The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 601–700 of 1,004
Guo, L., Hu, H., Jiang, N., Yang, H., Sun, X., Xia, H., Ma, J., & Liu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30819 · Cited by 23
Park, S. J., Kim, K. W., & Lee, E. J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00994 · Cited by 27
Kulisevsky, J. (2022) · Revista de Neurología · doi:10.33588/rn.75s04.2022217 · Cited by 30
DNA repair deficiencies and neurodegeneration
Ropert, B., Gallrein, C., & Schumacher, B. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103679 · Cited by 21
Aggregation and phase separation of α-synuclein in Parkinson's disease
Han, W., Wei, M., Xu, F., & Niu, Z. (2024) · Chemical Communications · doi:10.1039/d4cc01591f · Cited by 22
Petersen, J. J., Kamp, C. B., Faltermeier, P., Juul, S., Løkkegaard, A., Gluud, C., & Jakobsen, J. C. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2023-000705 · Cited by 28
Power of Multi-Modality Variables in Predicting Parkinson's Disease Progression
Jiang, Y., Yang, H.-J., Kim, J., Tang, Z., & Ruan, X. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3482180 · Cited by 26
Siwach, A., Patel, H., Khairnar, A., & Parekh, P. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70192 · Cited by 21
Lei, T., Fu, G., Xue, X., & Yang, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156553 · Cited by 21
Huang, Y.-B., Tian, L.-L., Zhu, Z., Zhou, K.-G., Lai, X., Peng, Y.-Z., Wu, Z., Tong, W., Wang, H., Wang, X., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156652 · Cited by 24
Voice analysis in Parkinson’s disease - a systematic literature review
Xavier, D., Felizardo, V., Ferreira, B., Zacarias, H., Pourvahab, M., Souza-Pereira, L., & García, N. M. (2025) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2025.103109 · Cited by 21
Aqeel, A., Akram, A., Ali, M., Iqbal, M., Aslam, M., Rukhma, & Shah, F. I. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112129 · Cited by 23
Aggregation of α-synuclein splice isoforms through a phase separation pathway
Röntgen, A., Toprakcioglu, Z., Dada, S., Morris, O. M., Knowles, T. P. J., & Vendruscolo, M. (2025) · Science Advances · doi:10.1126/sciadv.adq5396 · Cited by 25
Advances in research on mitochondrial dysfunction in neurodegenerative diseases
Zhang, Y., Li, X., Zhang, Y., & Li, X. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13101-4 · Cited by 25
Extracellular vesicles in age-related diseases: disease pathogenesis, intervention, and biomarker
Putri, P. H. L., Alamudi, S. H., Dong, X., & Fu, Y. L. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04374-7 · Cited by 25
Marano, G., Rossi, S., Marzo, E. M., Ronsisvalle, A., Artuso, L., Traversi, G., Pallotti, A., Bove, F., Piano, C., Bentivoglio, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13071764 · Cited by 27
Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson’s Disease: Current View
Hou, Y., & Shang, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.788846 · Cited by 21
LRRK2 and Proteostasis in Parkinson’s Disease
Pérez‐Carrión, M. D., Posadas, I., Solera, J., & Ceña, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126808 · Cited by 23
Shang, S., Zhu, S., Wu, J., Xu, Y. Q., Chen, L., Dou, W., Yin, X., Chen, Y., Shen, D., & Ye, J. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14037 · Cited by 21
Yang, C., Huang, J., Wang, T., Tan, Y.-C., Chen, Y., Zhao, Z., Qu, C.-H., & Qu, Y. (2022) · BMC Neurology · doi:10.1186/s12883-022-03027-z · Cited by 21
Zhang, C., Xue, Z. H., Zhu, L., Zhou, J., Zhuo, L., Zhang, J., Zhang, X., Liu, W., Han, L., & Liao, W. (2023) · Food & Function · doi:10.1039/d2fo02939a · Cited by 21
Microglia in brain aging: An overview of recent basic science and clinical research developments
Fan, H., Zhang, M., Wen, J., Wang, S., Yuan, M., Sun, H., Shu, L., Xu, Y., Pu, Y., & Cai, Z. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20220220 · Cited by 23
Animal models to study the neurological manifestations of the post-COVID-19 condition
Usai, C., Mateu, L., Brander, C., Vergara‐Alert, J., & Segalés, J. (2023) · Lab Animal · doi:10.1038/s41684-023-01231-z · Cited by 22
Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson’s disease
Cui, C., Song, H., Han, Y., Yu, H., Li, H., Yang, Y., & Zhang, B. (2023) · mSphere · doi:10.1128/msphere.00431-23 · Cited by 21
Cross talk about the role of Neuropeptide Y in CNS disorders and diseases
Bale, R., & Doshi, G. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102388 · Cited by 21
Immunity impacts cognitive deficits across neurological disorders
Shaw, B. C., Anders, V., Tinkey, R. A., Habean, M. L., Brock, O. D., Frostino, B. J., & Williams, J. L. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15999 · Cited by 27
Impact of TRPV1 on Pathogenesis and Therapy of Neurodegenerative Diseases
Wang, W., & Sun, T. (2023) · Molecules · doi:10.3390/molecules29010181 · Cited by 24
An update on new-age potential biomarkers for Parkinson’s disease
Soni, R., Mathur, K., & Shah, J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102208 · Cited by 21
Hypoxia Sensing and Responses in Parkinson’s Disease
Burtscher, J., Duderstadt, Y., Gatterer, H., Burtscher, M., Vozdek, R., Millet, G. P., Hicks, A. A., Ehrenreich, H., & Kopp, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031759 · Cited by 24
Al-Saad, O. M., Gabr, M. T., Darwish, S. S., Rullo, M., Pisani, L., Miniero, D. V., Liuzzi, G. M., Kany, A. M., Hirsch, A. K. H., Abadi, A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116266 · Cited by 23
A systematic review of salivary biomarkers in Parkinson’s disease
Bartolo, M. I. D., Belvisi, D., Mancinelli, R., Costanzo, M., Caturano, C., Leodori, G., Berardelli, A., Fabbrini, G., & Vivacqua, G. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01677 · Cited by 21
Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases
Iyer, S., Bhat, I., & Sheshappa, M. B. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300409 · Cited by 22
Mays, G. P., Hett, K., Eisma, J. J., McKnight, C. D., Elenberger, J., Song, A. K., Considine, C. M., Richerson, W. T., Han, C., Stark, A. J., et al. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00542-8 · Cited by 22
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 22
Mamo, A. A., Gebresilassie, B. G., Mukherjee, A., Hassija, V., & Chamola, V. (2024) · Cognitive Computation · doi:10.1007/s12559-024-10291-3 · Cited by 21
Qiu, R., Sun, W., Su, Y., Sun, Z., Fan, K., Liang, Y., Lin, X., & Zhang, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123088 · Cited by 23
Accelerating Parkinson’s Disease drug development with federated learning approaches
Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00837-5 · Cited by 21
Self-citationEndoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies
Kovács, G. E., Reimer, L., & Jensen, P. H. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.742625 · Cited by 22
Canonico, M., Artaud, F., Degaey, I., Moisan, F., Kabore, R., Portugal, B., Nguyen, T. T. H., Pesce, G., Boutron‐Ruault, M., Roze, E. F., et al. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00851-y · Cited by 21
Hülsmeier, A. J. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106851 · Cited by 22
Kwok, J. Y. Y., Chan, L. M. L., Lai, C. A., Ho, P. W., Choi, Z. Y.-K., Auyeung, M., Pang, S., Choi, E. P. H., Fong, D., Yu, D. S. F., et al. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000543457 · Cited by 23
Zhu, R., Han, R.-X., Chen, Y.-H., Huang, L., Liu, T., Jiang, J., Wang, C., Cao, L., Liu, Y., & Lu, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00818-z · Cited by 24
Culicetto, L., Cardile, D., Marafioti, G., Buono, V. L., Ferraioli, F., Massimino, S., Lorenzo, G. D., Sorbera, C., Brigandì, A., Vicario, C. M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1534073 · Cited by 20
Prasuhn, J., Kunert, L., & Brüggemann, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137263 · Cited by 20
Metabolomics of blood reveals age-dependent pathways in Parkinson’s Disease
D’Ascenzo, N., Antonecchia, E., Angiolillo, A., Bender, V., Camerlenghi, M., Xie, Q., & Costanzo, A. D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00831-5 · Cited by 21
Crosstalk between regulatory non-coding RNAs and oxidative stress in Parkinson’s disease
Zhang, H., Liu, X., Liu, Y., Liu, J., Gong, X., Li, G., & Tang, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.975248 · Cited by 22
Druggable transcriptomic pathways revealed in Parkinson’s patient-derived midbrain neurons
van den Hurk, M., Lau, S., Marchetto, M. C., Mertens, J., Stern, S., Corti, O., Brice, A., Winner, B., Winkler, J., Gage, F. H., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00400-0 · Cited by 21
Pandey, S. K., & Singh, R. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986668 · Cited by 22
Kim, C. J., Kwak, T. Y., Bae, M. H., Shin, H. K., & Choi, B. T. (2022) · Journal of pharmacopuncture · doi:10.3831/kpi.2022.25.4.326 · Cited by 20
Teng, X., Mao, S., Wu, H., Shao, Q., Zu, J., Zhang, W., Zhou, S., Zhang, T., Zhu, J., Cui, G., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15780 · Cited by 20
Wang, X., Li, S., Pun, C., Guo, Y., Xu, F., Gao, H., & Lu, H. (2023) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2023.3246961 · Cited by 20
Wang, X., Chen, X., Liu, G., Cai, H., & Le, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108614 · Cited by 20
Ye, Z., Li, C., Liu, S., Liang, H., Feng, J., Lin, D., Chen, Y., Peng, S., Bu, L., Tao, E., et al. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110604 · Cited by 20
Ren, J., Zhan, X., Zhou, H., Guo, Z., Xing, Y., Yin, H., Xue, C., Wu, J., & Liu, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14387 · Cited by 22
Shin, W., Lee, Y., Lim, J., Lee, Y. B., Lah, D., Lee, S., Lee, J.-U., Yu, R., Lee, P. H., Lee, J., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03899 · Cited by 20
Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson's disease
Imarisio, A., Yahyavi, I., Avenali, M., Maio, A. D., Buongarzone, G., Galandra, C., Picascia, M., Filosa, A., Gasparri, C., Monti, M. C., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106413 · Cited by 20
Elbatanouny, H., Kleanthous, N., Dahrouj, H., Alusi, S. H., Almajali, E. R., Mahmoud, S. A., & Hussain, A. J. (2024) · Sensors · doi:10.3390/s24123959 · Cited by 21
Tedeschi, R., Platano, D., Donati, D., & Giorgi, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154539 · Cited by 14
Correlations of gray matter volume with peripheral cytokines in Parkinson's disease
Chen, B., Zhou, H., Liu, X., Yang, W., Luo, Y., Zhu, S., Zheng, J., Wei, X., Chan, L. L., Tan, E., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106693 · Cited by 20
Lutein, a versatile carotenoid: Insight on neuroprotective potential and recent advances
Jayakanthan, M., Manochkumar, J., Efferth, T., & Ramamoorthy, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156185 · Cited by 22
Neuroprotective Effects of Cranberry Juice Treatment in a Rat Model of Parkinson’s Disease
Witucki, Ł., Kurpik, M., Jakubowski, H., Szulc, M., Mikołajczak, P. Ł., Jodynis‐Liebert, J., & Kujawska, M. (2022) · Nutrients · doi:10.3390/nu14102014 · Cited by 20
Leocadi, M., Canu, E., Sarasso, E., Gardoni, A., Basaia, S., Calderaro, D., Castelnovo, V., Volonté, M. A., Filippi, M., & Agosta, F. (2024) · Journal of Neurology · doi:10.1007/s00415-023-12151-w · Cited by 22
Böttinger, M. J., Labudek, S. E., Schoene, D., Jansen, C.-P., Stefanakis, M., Litz, E., Bauer, J. M., Becker, C., & Gordt, K. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02733-7 · Cited by 19
Li, Q.-M., Wu, S., Zha, X., Zang, D., Zhang, F., & Luo, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118363 · Cited by 20
Zhang, N., Zhang, S., & Dong, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116811 · Cited by 20
Kerdiles, O., Mi-mba, M.-F. O. M., Coulombe, K., Tremblay, C., Émond, V., Saint‐Pierre, M., Rouxel, C., Berthiaume, L., Julien, P., Cicchetti, F., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-00595 · Cited by 19
Single-cell sequencing of the substantia nigra reveals microglial activation in a model of MPTP
Liu, Q., Liu, Z., Xie, W., Li, Y., Wang, H., Zhang, S., Wang, W., Hao, J., Geng, D., Yang, J., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1390310 · Cited by 20
Chew, E. G. Y., Liu, Z., Li, Z., Chung, S. J., Lian, M. M., Tandiono, M., Heng, Y. J., Ng, E., Tan, L. C. S., Chng, W. L., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00760-7 · Cited by 23
Recent advances in molecularly imprinted polymers toward biomedical healthcare devices
Seo, Y., Kim, Y.-H., Kim, J., Jung, H. G., Jang, J. W., Kim, H., Hwang, K. S., Lee, D., Lee, S. W., Lee, J. H., et al. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117637 · Cited by 20
Dong, X., Yang, T., & Jin, Z. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01022-y · Cited by 18
Activatable small-molecule NIR fluorescent/photoacoustic probes for brain disease imaging
Zou, J., Kim, Y., Lee, Y., Hong, S. J., Lee, K., Zhang, F., Mao, Z., & Kim, J. S. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217149 · Cited by 20
Raković, A., Voß, D., Vulinović, F., Meier, B., Hellberg, A.-K., Nau, C., Klein, C., & Leipold, E. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.817198 · Cited by 18
Self-citationXia, N., Cabin, D. E., Fang, F., & Pera, R. A. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.894620 · Cited by 19
Flønes, I. H., Nyland, H., Sandnes, D. A., Alves, G. W., Tysnes, O., & Tzoulis, C. (2022) · Biomolecules · doi:10.3390/biom12060747 · Cited by 18
Zhao, Y., Zhang, K., Pan, H., Wang, Y., Zhou, X., Xiang, Y., Xu, Q., Sun, Q., Tan, J., Yan, X., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.889057 · Cited by 19
Zheng, R., Yan, Y., Pu, J., & Zhang, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169088 · Cited by 19
Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease
Rus, T., Schindlbeck, K. A., Tang, C. C., Vo, A., DHAWAN, V. M., Trošt, M., & Eidelberg, D. (2022) · Movement Disorders · doi:10.1002/mds.29188 · Cited by 19
Chiral Se@CeO 2 superparticles for ameliorating Parkinson's disease
Liu, X., Zhang, H., Hao, C., Kuang, H., Xu, C., & Xu, L. (2022) · Nanoscale · doi:10.1039/d2nr04534f · Cited by 19
Wu, J., Qin, C., Cai, Y., Zhou, J., Xu, D., Lei, Y., Fang, G., Chai, S., & Xiong, N. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-5756 · Cited by 19
Khosousi, S., Hye, A., Velayudhan, L., Bloth, B., Tsitsi, P., Markaki, I., & Svenningsson, P. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105313 · Cited by 21
The Early Treatment Phase in Parkinson’s Disease: Not a Honeymoon for All, Not a Honeymoon at All?
Cánovas, A. A., Voeten, J., Gifford, L., Thomas, O., Lees, A. J., & Bloem, B. R. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-225064 · Cited by 19
Self-citationCai, G., Shi, W., Wang, Y.-Q., Weng, H., Chen, L., Yu, J., Chen, Z., Lin, F., Ren, K., Zeng, Y., et al. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad101 · Cited by 19
Autophagy‑regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review)
Ma, Z., Liang, H., Hu, B., Cai, S., & Dong, Y. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5253 · Cited by 19
Zhang, Q., Chen, X., Chen, F., Wen, S., & Zhou, C. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175884 · Cited by 19
Cellular mechanisms of fibrin (ogen): insight from neurodegenerative diseases
Wen, T., & Zhang, Z. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1197094 · Cited by 19
Sheta, R., Teixeira, M., Idi, W., & Oueslati, A. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102486 · Cited by 19
Kaplan, A., Barkan-Slater, S., Zlotnik, Y., & Levy‐Tzedek, S. (2023) · International Journal of Human-Computer Studies · doi:10.1016/j.ijhcs.2023.103148 · Cited by 18
Capato, T., Rodrigues, R., Cury, R. G., Teixeira, M. J., & Barbosa, E. R. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1772769 · Cited by 19
Naphthoquinones as a Promising Class of Compounds for Facing the Challenge of Parkinson’s Disease
Santos, T. B., de Moraes, L. G. C., Pacheco, P. A. F., dos Santos, D. G., Ribeiro, R. M. D. A. C., Moreira, C. D. S., & da Rocha, D. R. (2023) · Pharmaceuticals · doi:10.3390/ph16111577 · Cited by 20
Liu, W., Zhang, W., Xing, L.-Z., Zhao, Y., Xu, J., Li, R.-J., & Zhang, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117529 · Cited by 20
Population fraction of Parkinson’s disease attributable to preventable risk factors
Payami, H., Cohen, G., Murchison, C., Sampson, T. R., Standaert, D. G., & Wallen, Z. D. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00603-z · Cited by 21
Salemi, M., Ravo, M., Lanza, G., Schillaci, F. A., Ventola, G. M., Marchese, G., Salluzzo, M. G., Cappelletti, G., & Ferri, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020707 · Cited by 19
Investigation of Scalograms with a Deep Feature Fusion Approach for Detection of Parkinson’s Disease
Cantürk, İ., & Günay, O. (2024) · Cognitive Computation · doi:10.1007/s12559-024-10254-8 · Cited by 19
Panaitescu, P.-Ș., Răzniceanu, V., Mocrei-Rebrean, Ș.-M., Neculicioiu, V. S., Dragoș, H.-M., Costache, C. A., & Filip, G. A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050244 · Cited by 20
Caronni, S., Sorbo, F. D., Barichella, M., Fothergill‐Misbah, N., Denne, T., Laguna, J., Urasa, S. J., Dekker, M. C. J., Akpalu, A. K., Sarfo, F. S., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106983 · Cited by 19
Kumari, S., Kamiya, A., Karnik, S. S., Rohilla, S., Dubey, S. K., & Taliyan, R. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04260-y · Cited by 20
Bagwell, E., & Larsen, J. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1451845 · Cited by 22
Domingos, J., Dean, J., Fernandes, J. B., & Godinho, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031281 · Cited by 20
Emerging Potential of Exosomal Non-coding RNA in Parkinson’s Disease: A Review
Zhang, P., Rasheed, M., Liang, J., Wang, C., Feng, L. P., & Chen, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.819836 · Cited by 19
Toledano‐Pinedo, M., Porro-Pérez, A., Schäker‐Hübner, L., Romero, F., Dong, M., Samadi, A., Almendros, P., Iriepa, I., Bautista‐Aguilera, Ó. M., Rodríguez‐Fernández, M. M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01367 · Cited by 19
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
